Pharmaceutical News

RSS

Treating traumatic brain-injured patients with anticoagulant decreases risk of dangerous clots

Researchers from the University of Missouri School of Medicine have found that a new protocol that uses preventive blood-thinning medication in the treatment of patients with traumatic brain injuries reduces the risk of patients developing life-threatening blood clots without increasing the risk of bleeding inside the brain.

19 Nov 2013

Research shows oral contraceptive use over three years could be a risk factor for glaucoma

Research presented today, at the 117th Annual Meeting of the American Academy of Ophthalmology in New Orleans, has found that women who have taken oral contraceptives for three or more years are twice as likely to suffer from glaucoma, one of the leading causes of blindness which affects nearly 60 million worldwide. The researchers caution gynecologists and ophthalmologists to be aware of the fact that oral contraceptives might play a role in glaucomatous diseases, and inform patients to have their eyes screened for glaucoma if they also have other risk factors.

19 Nov 2013

Vismodegib drug does not offer added benefits for patients with BCC

The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma: symptomatic metastatic BCC and locally advanced BCC inappropriate for surgery or radiotherapy.

19 Nov 2013

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration.

18 Nov 2013

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.

18 Nov 2013

Entire structure of health-care delivery needs to be re-engineered to address threat of antibiotic resistance

The entire structure of health-care delivery for effective antibiotics – from research and development, to distribution and rational use – needs to be re-engineered to address the looming global threat of antibiotic resistance, say the authors of a new report, published today [Sunday 17 November] in The Lancet Infectious Diseases, ahead of European Antibiotic Awareness Day, and the US Centers for Disease Control and Prevention (CDC) ‘Get Smart About Antibiotics Week’ on Monday 18 November.

18 Nov 2013

New hope for patients whose melanoma has metastasised to the brain

New data show that in patients whose melanoma (BRAF V600 mutation-positive) has spread (metastasised) to the brain, Zelboraf (vemurafenib) extends life expectancy by over six months compared to chemotherapy.1 These results are welcome news for patients suffering from metastatic melanoma, as up to half of these patients are diagnosed with brain metastases with many given less than six months to live.1

18 Nov 2013

NPS MedicineWise urges all health professionals to preserve the miracle of antibiotics

Marking the start of Antibiotic Awareness Week, NPS MedicineWise is urging all health professionals to pledge their commitment to preserve the miracle of antibiotics and re-shape consumer expectations of these lifesavings medicines.

18 Nov 2013

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Eisai announces today that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals.

18 Nov 2013

Study suggests potential new treatment for seizures

A study out today in the journal Nature Medicine suggests a potential new treatment for the seizures that often plague children with genetic metabolic disorders and individuals undergoing liver failure. The discovery hinges on a new understanding of the complex molecular chain reaction that occurs when the brain is exposed to too much ammonia.

17 Nov 2013

Errors in medication common on admission to mental health services, shows study

A recent study, published in the International Journal of Clinical Pharmacy, involving Aston University (UK), South Essex Partnership University NHS Foundation Trust (SEPT) and the University of East Anglia (UK) found medication errors were common on admission to mental health services.

16 Nov 2013

Studies prove that students use prescription drugs to enhance cognitive performance

American and European studies prove that students use prescription medication or drugs to enhance their cognitive performance. Researchers from the universities of Zurich and Basel examined whether Swiss students have also experimented with neuroenhancement and which substances they take by conducting a survey of 6,725 students with an average age of 23 at the two universities and ETH Zurich.

16 Nov 2013

GO drug may improve outcome of bone marrow transplantation for select pediatric leukemia patients

Combining the drug gemtuzumab ozogamicin with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia, according to a study led by St. Jude Children's Research Hospital. The results appear in the current edition of the journal Cancer.

16 Nov 2013

Diplomat selected as provider of IMBRUVICA capsules for MCL treatment

Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.

16 Nov 2013

Intelliject to be recognized with George DiDomizio Industry Award

The Institute for Safe Medication Practices has announced that this year's George DiDomizio Industry Award is being presented to Intelliject, Inc. for pioneering advances in drug/device combination products with the Auvi-Q epinephrine auto-injector (also known as Allerject™ in Canada). Auvi-Q is the first auto-injector with audio as well as visual cues for the emergency treatment of life-threatening allergic reactions.

16 Nov 2013

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that its wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd., has entered into a supply arrangement with Pharmacyclics, Inc.

15 Nov 2013

New Malaria Vaccine Technology Roadmap aims to identify second generation malaria vaccines

The world should aim to have vaccines which reduce malaria cases by 75%, and are capable of eliminating malaria, licensed by 2030, according to the updated 2013 "Malaria Vaccine Technology Roadmap", launched today.

15 Nov 2013

TPI’s revenue decreases 8.1% to $14.8 million in first quarter fiscal year 2014

Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter fiscal year 2014.

15 Nov 2013

Conceive Plus Fertility Personal Lubricant receives FDA approval

The Pew Research Center reports that in the year 2011, the birth rate in the United States slid by 8%. That kind of statistic would indicate getting pregnant isn't as easy as it used to be. However, pharmaceutical manufacturer SASMAR aims to be at the forefront of helping couples to start families. The FDA has officially approved their OTC sperm friendly fertility personal lubricant, Conceive Plus for sale in the US market.

15 Nov 2013

European Commission grants marketing authorization for Bayer HealthCare's Xofigo injection

Bayer HealthCare announced today that the European Commission has granted marketing authorization for Xofigo (radium Ra 223 dichloride) solution for injection for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. This decision follows a positive recommendation from the European Committee for Medicinal Products for Human Use in September of this year.

15 Nov 2013

Pharmaceutical News

Treating traumatic brain-injured patients with anticoagulant decreases risk of dangerous clots

Research shows oral contraceptive use over three years could be a risk factor for glaucoma

Vismodegib drug does not offer added benefits for patients with BCC

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Entire structure of health-care delivery needs to be re-engineered to address threat of antibiotic resistance

New hope for patients whose melanoma has metastasised to the brain

NPS MedicineWise urges all health professionals to preserve the miracle of antibiotics

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Study suggests potential new treatment for seizures

Errors in medication common on admission to mental health services, shows study

Studies prove that students use prescription drugs to enhance cognitive performance

GO drug may improve outcome of bone marrow transplantation for select pediatric leukemia patients

Diplomat selected as provider of IMBRUVICA capsules for MCL treatment

Intelliject to be recognized with George DiDomizio Industry Award

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

New Malaria Vaccine Technology Roadmap aims to identify second generation malaria vaccines

TPI’s revenue decreases 8.1% to $14.8 million in first quarter fiscal year 2014

Conceive Plus Fertility Personal Lubricant receives FDA approval

European Commission grants marketing authorization for Bayer HealthCare's Xofigo injection

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News